Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey

Kawai, Hiroki; Ohtsu, Atsushi; Boku, Narikazu; Hamamoto, Yasuo; Nagashima, Fumio; Muto, Manabu; Sano, Yasushi; Mera, Kiyomi; Yano, Tomonori; Doi, Toshihiko; Yoshida, Shigeaki

doi:10.1007/s10120-003-0216-9

Cited by 14 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Representative adverse reac-tions with S-1 include decreases in hematocrit level, leukopenia, granulocytopenia, diarrhea, malaise, and proteinuria [1]. A postmarketing survey suggested that toxicities were generally mild and that outpatient treatment with this agent would be feasible [11]. The present patient developed none of these adverse reactions during neoadjuvant chemotherapy or during the perioperative period.…”

Section: Discussionmentioning

confidence: 59%

Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy

et al. 2006

View full text Add to dashboard Cite

Single-agent or combined chemotherapy with the novel oral fluoropyrimidine anticancer drug, S-1 (TS-1), has been reported to be useful for the treatment of advanced gastric cancer. Here, we report a patient with advanced gastric cancer achieving a complete response (CR) after 2 weeks of administration of S-1 as neoadjuvant chemotherapy. A 78-year-old woman with epigastric pain was diagnosed as having advanced gastric cancer. S-1 was administered orally, at a dose of 50 mg twice a day every day for 2 weeks, followed by a 2-week drug-free period. No obvious adverse reactions occurred. Subsequently, the patient underwent distal partial gastrectomy with D2 lymph node dissection. Pathological examination indicated no remnant signet-ring cells in the excised specimen, no lymph node metastasis, and unnatural fibrosis in one of the No. 3 lymph nodes. The neoadjuvant chemotherapy induced a CR according to the Japanese classification of gastric carcinoma.

show abstract

Section: Discussionmentioning

confidence: 59%

Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy

et al. 2006

View full text Add to dashboard Cite

show abstract

“…A previous study demonstrated that S-1 is a superior oral chemotherapy drug for advanced gastric cancer and suggested that it may be effective as preoperative chemotherapy [9]. Common side effects of S-1 include a low hematocrit count, leukopenia, granulocytopenia, diarrhea, lethargy, and proteinuria; a post-marketing survey revealed generally low toxicity and suggested that S-1 can be administered on an outpatient basis [10].…”

Section: Discussionmentioning

confidence: 99%

Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer

et al. 2020

View full text Add to dashboard Cite

Gastric cancer incidence is high in several countries, and management of advanced gastric cancer remains a challenge. Chemotherapy for unresectable gastric cancers is still evolving, and achieving a complete cure is difficult. Although a clinical complete response to chemotherapy has been reported in patients with unresectable gastric cancer, the chemotherapy duration for these patients is unclear. Here, we report the case of a 71-year-old man who presented with abdominal discomfort. Upper endoscopy revealed advanced gastric cancer on the upper gastric body. Histopathological examination revealed a poorly differentiated adenocarcinoma. Computed tomography revealed regional lymph node and multiple bilobar hepatic metastases. Radical surgery was not possible; therefore, palliative resection of the primary lesion was planned for symptomatic improvement. Tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate were administered prior to surgery, and proximal gastrectomy was performed. Tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate administration was reinitiated after surgery. A clinical complete response was achieved in the 8th postoperative month, with no hepatic metastases noted on radio imaging. Computed tomography performed in the 1st postoperative year revealed ascites; however, the cytological examination findings were negative. The initial chemotherapy was discontinued, and paclitaxel administration was commenced. Computed tomography performed annually thereafter demonstrated no recurrence, and paclitaxel was discontinued in the 9th postoperative

show abstract

“…Diffuse-type gastric carcinoma, according to the Lauren classification, is highly metastatic and characterized clinically by rapid disease progression and poor prognosis. Studies have shown that diffuse-type gastric cancer patients were more sensitive to S-1 chemotherapy than intestinal-type ones [38][39][40][41]. However, there are no reports demonstrating the correlation of Lauren classification with 5-FU metabolic enzymes.…”

Section: Discussionmentioning

confidence: 99%

OPRT Is a Potential Predictive Factor for the Response to S-1 in Gastric Cancer

Li¹,

Leong²,

Yuan³

et al. 2013

JCT

View full text Add to dashboard Cite

Objective: To analyze the impact of mRNA expression of oral fluoropyrimidine (S-1) metabolism (thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyltransferase [OPRT]), on treatment outcomes in locally advanced gastric cancer patients receiving preoperative S-1 combined with oxaliplatin chemotherapy. Methods: Preoperative stage III gastric cancer patients received S-1 (80 mg/m²/day; days 1-14) and oxaliplatin (130 mg/m²; day 1) every 3 weeks and subsequently received gastrectomy with D1/D2 lymphadenectomy. Paired tumor and normal fresh frozen tissues were collected to evaluate mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase using quantitative reverse-transcriptase polymerase chain reaction. Results: Between December 2009 and October 2010, thirty-five patients were enrolled in this study. 24 (68.5%) patients had clinical tumor response and 10 (28.6%) patients achieved histological response. Quantitative reverse-transcriptase polymerase chain reaction results showed that orotate phosphoribo-syltransferase (OPRT) mRNA expression was significantly higher in histological responders than non-responders (3.75 vs. 1.81, P = 0.005). Diffuse-type gastric cancer patients demonstrated higher orotate phosphoribosyltransferase (OPRT) expression levels than intestinal-type ones (2.79 vs. 1.60, P = 0.014). Similar results were not found when comparing thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels. Conclusion: Orotate phosphoribosyltransferase (OPRT) expression level may be a potential predictive biomarker in advanced gastric cancer patients treated with oral fluoropyrimidine (S-1) based chemotherapy. Mini Abstract: Orotate phosphoribosyltransferase (OPRT) expression level may be a potential predictive biomarker in advanced gastric cancer patients treated with oral fluoropyrimidine (S-1) based chemotherapy.

show abstract

Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey

Cited by 14 publications

References 13 publications

Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy

Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy

Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer

OPRT Is a Potential Predictive Factor for the Response to S-1 in Gastric Cancer

Contact Info

Product

Resources

About